Rationale:
Complement is crucial for host defense but may also drive dysregulated inflammation. There is limited understanding of alternative complement function, which can amplify all complement activity, during critical illness.
Objectives:
We examined the function and key components of the alternative complement pathway in a series of critically ill patients and in a mouse pneumonia model.
Methods:
Total classical (CH50) and alternative complement (AH50) function were quantified in serum from 321 prospectively enrolled critically ill patients and compared with clinical outcomes. Alternative pathway (AP) regulatory factors were quantified by ELISA (
n
= 181) and examined via transcriptomics data from external cohorts. Wild-type,
Cfb
−/−
, and
C3
−/−
mice were infected intratracheally with
Klebsiella pneumoniae
(KP) and assessed for extrapulmonary dissemination.
Measurements and Main Results:
AH50 greater than or equal to median, but not CH50 greater than or equal to median, was associated with decreased 30-day mortality (adjusted odds ratio [OR], 0.53 [95% confidence interval (CI), 0.31–0.91]), independent of chronic liver disease. One-year survival was improved in patients with AH50 greater than or equal to median (adjusted hazard ratio = 0.59 [95% CI, 0.41–0.87]). Patients with elevated AH50 had increased levels of AP factors B, H, and properdin, and fewer showed a “hyperinflammatory” subphenotype (OR, 0.30 [95% CI, 0.18–0.49]). Increased expression of proximal AP genes was associated with improved survival in two external cohorts. AH50 greater than or equal to median was associated with fewer bloodstream infections (OR, 0.67 [95% CI, 0.45–0.98). Conversely, depletion of AP factors, or AH50 less than median, impaired
in vitro
serum control of KP that was restored by adding healthy serum.
Cfb
−/−
mice demonstrated increased extrapulmonary dissemination and serum inflammatory markers after intratracheal KP infection compared with wild type.
Conclusions:
Elevated AP function is associated with improved survival during critical illness, possibly because of enhanced immune capacity.